International Medical Journal (ISSN:13412051)

Aim and Scope

Aim-

International Medical Journal ISSN: (13412051) is an international open-access journal publishes twelve times each year. The "International Medical Journal" is a peer-reviewed, monthly, online international research journal, which publishes original articles, research articles, review articles with top-level work from all areas of Medical Science Research and their application including Aetiology, bioengineering, biomedicine, cardiology, chiropody, ENT etc. Researchers in all Medical Science and Pharmacy fields are encouraged to contribute articles based on recent research. Journal publishes research articles and reviews within the whole field of Medical Science and Pharmacy Research, and it will continue to provide information on the latest trends and developments in this ever-expanding subject. International Medical Journal journal covers almost all disciplines of Medical Science and Pharmacy. Researchers and students of M.B.B.S, M.D., D.T.C.D., GYNE., M.S., M.Pharma, And PhD are requested to send their original research articles to International Medical Journal.

Scope-

International Medical Journal ISSN: (13412051) is a peer-reviewed journal. The journal seeks to publish original research articles that are hypothetical and theoretical in its nature and that provide exploratory insights in the following fields but not limited to:

Anatomy Physiology Biochemistry Pharmacology
Pathology Forensic medicine Microbiology Community Medicine
Otorhinolaryngology Internal Medicine General Surgery Obstetrics and Gynecology
Radiology Pulmonary Medicine Dermatology and Venereal diseases Infectious Diseases AMA, Agricultural Mechanization in Asia, Africa and Latin America Teikyo Medical Journal Journal of the Mine Ventilation Society of South Africa
Anaesthesia Cancer research Neurosurgery Orthopedics

See More Scopes

Latest Journals
International Medical Journal
Journal ID : IMJ-15-11-2020-657
Total View : 19

Abstract : The surgical intervention on chronic anal fissure is still the first line of treatment for this disease. The importance of this research lies in finding a new treatment for one of the most common anal lesions, and to choose a safe and effective method in the treatment of chronic anal fissure, avoiding the risks of anesthesia and surgery. To compare the surgical treatment (Lateral Internal Sphincterotomy) and topical treatment (Diltiazem Gel 2%), in terms of the ability to heal, studying the degree of symptoms regression after the treatment (bleeding/pain), and studying the incidence of gas / fecal incontinence. A prospective pilot study, which included 60 patients divided into two groups equally, Group A (30 patients who underwent surgical treatment), Group B (30 patients who underwent topical drug treatment with Diltiazem 2% gel), and the study was conducted at Tishreen University Hospital in Latakia – Syria, in the period between 2019-2020. In group A, complete recovery occurred in 29 patients (96.6%), anal bleeding decreased in all patients (100%), pain feeling decreased in all patients (100%), and gas incontinence occurred only in 4 patients (13.3%). Fecal incontinence didn't occur. In group B, complete recovery occurred in 17 patients (56.6%), anal bleeding decreased in 17 patients (68%), pain feeling decreased in 17 patients (65.3%), and gas / fecal incontinence didn't occur at all. Lateral internal Sphincterotomy is still the first line of treatment in patients with a chronic anal fissure, but drug therapy with (Diltiazem 2% gel) can be applied to patients who refuse surgical treatment, or for those who have contraindications for surgical intervention.
Full article
International Medical Journal
Journal ID : IMJ-04-11-2020-648
Total View : 347

Abstract :

The human life expectancy has increased 8% globally. Consistently, the aging population has also grown significantly. The increase of aging population is followed by many health issues, including, musculoskeletal pain. Low back pain (LBP) has been the key role of causing disability among musculoskeletal problems. Currently, American College of Physicians (ACP) recommended that nonpharmacologic treatment should be the first option in treating LBP. There are many studies about the effectiveness of cupping therapy (CT) in management LBP. Therefore, this review aims to outline the evidence of CT in treating LBP. The general conclusion of this review is CT can be a promising therapy as nonpharmacologic management of LBP.

.
Full article
International Medical Journal
Journal ID : IMJ-30-10-2020-646
Total View : 343

Abstract : For an objective and comprehensive assessment of all indicators of the quality of life of patients, the questionnaire “MOS SF-36 - Health Status Survey” was used. A specific questionnaire “Quality of life after myocardial infarction” - Quality of Life after Myocardial Infarction (QLMI) was also used. The total number of patients included in the study was 120, of whom 75 were men and 45 women, 62.5% and 37.5%, respectively. All patients were divided into three groups. The first group included 40 practical healthy patients. The second group is also represented by 40 patients who had myocardial infarction without complications, and the 3rd group included 40 patients who had myocardial infarction and who had complications. Indicators of the physical component of QL in patients with myocardial infarction in the second and third groups were reduced by a factor of 2-3 compared with the control group (1) and were significantly different in all indicators, especially in 1– Physical functioning by 60–75%, 2 - by role functioning by 30–55%, 3 by the intensity of pain by 33–73%, and 4 by the general state of health by 32.5– 52.5%. Indicators of quality of life, psychological component in patients undergoing myocardial infarction without complication and with complications, were significantly lower compared to practically healthy people in the following sequence: by vital activity by 32.5-45%, by role functioning, due to emotional state by 23, 9-57.3%, mental health by 32-44%, and social functioning by 20.5-62.5%. The results of the study showed that the indicators of the physical and psychological component of QL in patients after myocardial infarction, with and without complications, were 2-3 times lower than in the control group (p <0.05; p <0.01; p <0.001), indicating the effect of myocardial infarction on QOL.
Full article
International Medical Journal
Journal ID : IMJ-30-10-2020-645
Total View : 340

Abstract : Successful recovery of severe COVID-19 with cytokine storm with Plasma Convalescent Therapy or Extracorporeal blood purification, has been with or without methylprednisolone has been reported, but not in diabetes comorbid which in immunocompromised where cortisone is immunosuppressant. So cortisone for anti- inflammation drugs should be not recommended. This study builds the potential benefit and harm of corticosteroid in pandemic COVID-19. Systematic Review with Science Direct search engine using keywords of methylprednisolone and COVID-19 are used. Bayesian analysis and network support this study. Cytokine storm and anti- inflammation/ immunosuppressant and immunocompromised/ comorbid are used. Insulin Resistance Syndrome cases are included, and non is excluded. Pneumonia and DIC as the excess, ventilated patients are also included. Flowchart of 15 references supported the table, one table describe the references. Three Systematic Reviews, 4 case reports, 2 cohorts, 4 reviews, 2 observational with minimal 15,385 subjects. The use of corticosteroid as prevention, treatment, and rehabilitation at mild, medium, severe phases are recorded and analyzed. Cortisone is immunosuppressant stuff that should be used only in a hospitalized patient in critical severe cases in overwhelmed/ hyperinflammatory stage COVID-19 pts. but should be forbidden (not recommended is not enough) in comorbidities. Using cortisone in plant/OTC in this pandemic era should be socialized the danger in the public domain to combat the easy spread.
Full article
International Medical Journal
Journal ID : IMJ-28-10-2020-644
Total View : 331

Abstract :

More evidence confirmed the dopaminergic system involvement in ulcerative colitis (UC) pathogenesis. Genes, coding for D3 dopamine receptor were found in neuromuscular and mucosal layers in colon, as well as on immune cells mostly of primary immune response which indicates D3 receptor as the potential therapeutic target for UC. In present study we checked the hypothesize on the protective role of D3 receptor agonist in experimental models of UC. We used two models of UC: 6% iodoacetamide (IA)-induced UC in Wistar rats (0.1 ml, i.c.); and spontaneously developed colitis in IL-10 KO mice. Rats with IA-induced UC were treated with D3R agonist 7-OH-DPAT (in doses of 0.2 mg/kg and 1 mg/kg, s.c. on the 2nd and 5th days). Autopsy on the 7th day. Clinical, macroscopic and microscopic evaluation of UC were performed. It was indicated that during the normal condition D3R were localized on epithelial, endothelial and enteric neurons of rat’s colon mucosa. During the development of IA-induced UC in rats and UC in IL-10 KO mice, expression of D3R protein markedly decreased and its expression was observed mainly on the surface colonocytes. Treatment with 7-OH-DPAT in dose of 0.2 mg/kg had positive effect on clinical and morphological signs of IA-induced UC in rats. The administration of 7-OH-DPAT altered the mucus composition, also enhanced mast cell and macrophage functional reserve. Activation of D3 dopamine receptor might be the potential molecular target for UC treatment.

.
Full article

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates